Compare Becton Dickinson and Co (BDX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs WD 40 Company — how do they compare? Becton Dickinson and Co trades at $156.46 (market cap $41.51B), while WD 40 Company trades at $249.39 (market cap $3.35B). The key difference: Becton Dickinson and Co is far larger — about 12.4× WD 40 Company's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | WDFC | |
|---|---|---|
Market Cap | $41.51B | $3.35B |
Sector | Health | Technology |
52-Week High | $185.39 | $264.91 |
52-Week Low | $135.49 | $187.52 |
Enterprise Value | $57.97B | $3.40B |
Dividend Yield | 2.79% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
WDFC trades at $251.43, down 5.09% today but maintains a bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings of $2.33 per share, beating estimates by 47%, driven by broad-based sales growth. Valuation remains elevated with a P/E of 37.88 and P/S of 5, while profitability metrics show a net income margin of 13.22% and ROE of 11%. Recent news highlights WD-40's strong brand moat and inclusion in Zacks' Strong Buy list on July 15, 2026.
Outlook is positive given earnings momentum and brand strength, but high valuation and margin pressures from input costs pose risks. Analyst consensus is mixed with 71% hold ratings, suggesting cautious optimism. The stock offers growth potential but requires monitoring of cost management and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
